Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus investigator's choice therapy in platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck
jRCT2080222596Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: overall survival. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080222596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222596.